Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Endonovo Therapeutics Inc (ENDV)

Endonovo Therapeutics Inc (ENDV)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 1,303
  • Shares Outstanding, K 1,002,549
  • Annual Sales, $ 80 K
  • Annual Income, $ -6,440 K
  • 60-Month Beta 2.12
  • Price/Sales 6.86
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.01
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 11/19/19
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0011 +18.18%
on 12/18/19
0.0050 -74.00%
on 11/20/19
-0.0033 (-71.74%)
since 11/19/19
3-Month
0.0011 +18.18%
on 12/18/19
0.0134 -90.30%
on 10/02/19
-0.0057 (-81.43%)
since 09/19/19
52-Week
0.0011 +18.18%
on 12/18/19
0.0409 -96.82%
on 01/15/19
-0.0187 (-93.50%)
since 12/19/18

Most Recent Stories

More News
Endonovo Therapeutics Announces Issuance of Broad Patent Covering Electromagnetic Treatment of Multiple Sclerosis

� This furthers Endonovo's strategy to commercialize and protect its Electroceutical(s)

ENDV : 0.0013 (-7.14%)
Endonovo Therapeutics Announces Issuance of U.S. Patent Covering Apparatus and Method for Electromagnetic Treatment of Neurological Injury or Condition Caused by a Stroke

Issuance of U.S. Patent No. 15217855 Further Bolsters Endonovo's Intellectual Patent Portfolio

ENDV : 0.0013 (-7.14%)
Endonovo Therapeutics Provides SofPulse(R) To All NFL Teams [Updated]

Endonovo Therapeutics, Inc. (OTCQB: ENDVD) ("Endonovo" or the "Company"), announced today the delivery of SofPulse evaluation units to all thirty-two National Football League ("NFL") teams.

ENDV : 0.0013 (-7.14%)
ENDVD : 1.2400 (-4.62%)
Endonovo Therapeutics Provides SofPulse(R) To All NFL Teams

Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), announced today the delivery of SofPulse evaluation units to all thirty-two National Football League ("NFL") teams.

ENDV : 0.0013 (-7.14%)
Endonovo Therapeutics Announces Effective Date of Previously Announced Reverse Split of Common Stock

Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), announced today that its previously announced 1-for-1,000 reverse split of its common stock will become effective as of December...

ENDV : 0.0013 (-7.14%)
Endonovo Therapeutics Announces Reverse Stock Split - UPDATE

Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), announced today it has determined to effect a 1-for-1,000 reverse stock split of the Company's issued common shares.

ENDV : 0.0013 (-7.14%)
Endonovo Therapeutics Announces Reverse Stock Split

Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), announced today it has determined to effect a 1-for-1,000 reverse stock split of the Company's issued common shares.

ENDV : 0.0013 (-7.14%)
Endonovo Therapeutics Reports Third Quarter 2019 Results

Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), announced today its financial results for the quarter ended September 30, 2019.

ENDV : 0.0013 (-7.14%)
Endonovo Therapeutics Announces Reverse Stock Split

Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company") today announced that it had filed a preliminary information statement with respect to a proposed a reverse stock split of its common...

ENDV : 0.0013 (-7.14%)
Endonovo Therapeutics Appoints Dr. William Li as Strategic Advisor to the CEO

Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company") today announces it has appointed Dr. William Li as Strategic Advisor to the CEO. Dr. Li and Endonovo CEO Alan Collier will work collaboratively...

ENDV : 0.0013 (-7.14%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Trade ENDV with:

Key Turning Points

2nd Resistance Point 0.0022
1st Resistance Point 0.0018
Last Price 0.0013
1st Support Level 0.0011
2nd Support Level 0.0008

See More

52-Week High 0.0409
Fibonacci 61.8% 0.0257
Fibonacci 50% 0.0210
Fibonacci 38.2% 0.0163
Last Price 0.0013
52-Week Low 0.0011

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar